Serum Carbohydrate Antigen 19-9 as an Indicator of Liver Metastasis in Colorectal Carcinoma Cases

Hang, Dong; Tang, Jie; Li, Longhao; Ge, Jun; Chen, Xin; Ding, Jing; Men, Hai-Tao; Luo, Wuxia; Du, Yang; Liu, Cong; Zhao, Feng; Chen, Ye; Cheng, Ke; Liu, Jiyan

doi:10.7314/apjcp.2013.14.2.909

Cited by 21 publications

(21 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35% to 58% following the resection of colorectal liver metastases, with a median survival ranging from 33 to 46 months (Castaing et al, 2009;Hsu et al, 2011;Dong et al, 2013). Disease-free survival was 17.9% at 5 years, consistent with the 5-year disease-free survival rates of 15% to 25% reported in the literature (Castaing et al, 2009;Hsu et al, 2011).…”

Section: Figure 3 Overall Survival Curve For 22 Patients Who Underwesupporting

confidence: 81%

“…The liver is the most frequent (approximately 33%) metastatic site (Van Cutsem et al, 2006;Cui et al, 2013). Colorectal liver metastases (CLM) are present in 15% to 25% of cases at the time of diagnosis of the primary tumor (synchronous metastases), and approximately half of the patients undergoing radical resection of CRC will develop metastatic disease (metachronous metastasis) (Van Cutsem et al, 2006;Dong et al, 2013). Nearly 50%-60% of patients with colorectal cancer will eventually develop metastatic disease during the course of their disease (Van Cutsem et al, 2006;Hsu et al, 2011;Dong et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…Surgical resection remains at the present time the only potentially curative treatment for patients with CLM (Van Cutsem et al, 2006;Dong et al, 2013). Five-year survival after curative resection ranges 30%-40% (up to 60% in selected series), whereas less than 2% of patients are alive 5 years after diagnosis without surgical therapy (Castaing et al, 2009;Hsu et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

Cokmert¹,

Ellıdokuz²,

Demir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The purpose of this study was to analyze our series of liver resections for metastatic colorectal carcinoma (mCRC) to determine prognostic factors affecting survival and to evaluate the potential roles of neoadjuvant or adjuvant chemotherapy. Materials and Methods: Ninety-nine patients who underwent metastasectomy for liver metastases due to colorectal cancer at the Department of Medical Oncology, 9 Eylul University Hospital between 1996 and 2010 were evaluated in this study. The patients were followed through July 2013. Demographic, perioperative, laboratory, radiological and chemotherapy as well as survival data were obtained by retrospective chart review. Results: In 47 (47.5%) patients, liver metastases were unresectable at initial evaluation; the remaining 52 (52.5%) patients exhibited resectable liver metastases. Simultaneous hepatic resection was applied to 52 (35.4%) patients with synchronous metastasis, whereas 5 (64.5%) patients underwent hepatic resection after neoadjuvant chemotherapy. Forty-two patients with metachronous metastasis underwent hepatic resection following neoadjuvant chemotherapy. R0 resection was obtained in 79 (79.8%) patients. A second hepatectomy was performed in 22 (23.2%) patients. Adjuvant chemotherapy was given to 85 (85.9%) patients after metastasectomy. The median disease-free and overall survivals after initial metastasectomy were 12 and 37 months, respectively, the 1-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) rates being 46.5%, 24.3% and 17.9%and 92.3%, 59.0% and 39.0%, respectively. On multivariate analysis, the primary tumor site, tumor differentiation, resection margin and DFS were independent factors predicting better overall survival. Conclusions: In selected cases, hepatic metastasectomy for mCRC to the liver can result in long-term survival. Neoadjuvant chemotherapy did not exert a positive effect on DFS or OS. Adjuvant chemotherapy also did not appear to impact DFS and OS.

show abstract

Section: Figure 3 Overall Survival Curve For 22 Patients Who Underwesupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

Cokmert¹,

Ellıdokuz²,

Demir³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…A study reported that the survival decreased among patients with high pre-operative CEA levels and that the pre-operative CEA was correlated with tumor, tumor invasion depth, lymph node condition, stage, and post-operative recurrence (Wang et al, 2007). Many studies reported that when evaluated together, CEA and CA 19-9 levels increase sensitivity and specificity and that high levels indicate poor prognosis, where PFS and OS decreased significantly (Dixon et al, 2003;Wang et al, 2007;Sun et al, 2009;Dong et al, 2013;Sisik et al, 2013). Some studies conducted on CA 19-9 reported that it was of greater sensitivity than CEA in case of advanced stage diseases (Wang et al, 2002;Mourtzikou et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients

Eker¹,

Özaslan²,

Karaca³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Similar to our study, they did not find a correlation between increased CEA value and advanced TNM stage, however, there was a statistically significant correlation between increased CA 19-9 value and advanced stage. In another study Hang Dong et al (2013) suggested that the CA 19-9 might be a potential valuable indicator for liver metastasis of colorectal carcinom in the clinic.This shows the correlation between advaned stage colorectal cancer and high values of CA 19-9. Harada et al (1994) studied tumor markers in 52 gastric cancer patients and found the following positivity rates: 9.6% for CEA, 2.3% for AFP, 25% for CA 19-9, and 8.1% for CA 125.…”

Section: Discussionmentioning

confidence: 99%

CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients

Şişik¹,

Kaya²,

Baş³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The purpose of this study was to assess the predictive effect of preoperative CEA and CA 19-9 levels on the prognosis of colorectal and gastric cancer patients. Materials and Methods: CEA and CA 19-9 were evaluated preoperatively in patients undergoing surgery for colorectal cancer (n=116) and gastric cancer (n=49). Patients with CEA levels <5 ng/mL were classified as CEA Group 1, 5-30 ng/mL as CEA Group 2 and >30 ng/ mL were classified as CEA Group 3. Similarly the patients with a CA 19-9 level <35 U/mL were classified as CA 19-9 Group 1, with 35-100 U/mL as Group 2 and with >100 U/mL as Group and 3. TNM stages and histologic grades were noted according to histopathological reports. Patients with a TNM grade 0 or 1 were classified as Group A, TNM grade 2 patients constituted Group B and TNM grade 3 and 4 patients constituted Group C. Demographic characteristics, tumor locations and blood types of the patients were all recorded and these data were compared with the preoperative CEA and CA19-9 values. Results: A significant correlation between CA 19-9 levels (>100 U/mL) and TNM stage (in advanced stages) was determined. We also determined a significant correlation between TNM stages and positive vlaues for both CEA and CA 19-9 in colorectal and gastric cancer patients. In comparison between CEA and CA 19-9 levels and age, gender, tumor location, ABO blood group, and tumor histologic grade, no significant correlation was found. Conclusions: Positive levels of both CEA and CA 19-9 can be considered to indicate an advanced stage in colorectal and gastric cancer patients.

show abstract

Serum Carbohydrate Antigen 19-9 as an Indicator of Liver Metastasis in Colorectal Carcinoma Cases

Cited by 21 publications

References 21 publications

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients

CEA and CA 19-9 are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients

Contact Info

Product

Resources

About